Muhammad Kashif

4PUBLICATIONS
11CO-AUTHORS
Medical mycologyCancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Nov 03, 2023
Minimal residual disease status is the prognostic determinant following high-dose treatment for patients with multiple myeloma.

Hareth Nahi, Gabriel Afram, Katarina Uttervall

|Sep 06, 2022
Conditioning with melphalan 200 mg/m2 and subsequent ASCT improves progression-free and overall survival in elderly myeloma patients compared to standard of care.

Gabriel Afram, Roza Chaireti, Katarina Uttervall

|Sep 15, 2021
Antibody response to COVID-19 mRNA vaccine (Comirnaty) in myeloma patients treated with high-dose melphalan and/or immunotherapy.

Sandra Lockmer, Katarina Uttervall, Muhammad Kashif

|Apr 26, 2021
Low dose venetoclax as a single agent treatment of plasma cell malignancies harboring t(11;14).

Hareth Nahi, Muhammad Kashif, Monika Klimkowska

Pageof 1

Frequent Collaborators

1 joint publications

Charlotte Gran

1 joint publications

Robert Månsson

1 joint publications

Gabriel Afram

1 joint publications

Roza Chaireti